Alamar is a hypergrowth, wide-moat medical-device company whose price has already reached the analyst target, leaving an expensive valuation and heavy insider selling. The growth is real, but the price offers almost no margin of safety.
Thesis pillars
- Hypergrowth Revenue→Stable
- Wide Moat Quality→Stable
- Target Already Reached→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026
Alamar Biosciences, Inc. (ALMR) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $30.60, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8).
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein... Read more
Hold if already holding. Not a fresh buy at $30.60, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8). Chart setup: No clear chart pattern; technical signals are mixed. Downgraded from BUY WAIT — price $30.60 has reached target $30.80. No upside to wait for. Score 5.8/10, moderate confidence.
Passes 5/8 gates (positive momentum, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and clean insider activity and earnings proximity 1d<=7d. Suitability: aggressive.
Recent developments
updated 2026-11-02Recent Developments — Alamar Biosciences, Inc.
Latest news
- NEWS Analysts Offer Insights on NA Companies: Alamar Biosciences, Inc. (ALMR), NIQ Global Intelligence PLC (NIQ) and Amentum — The Globe and Mail neutral
- NEWS Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - RTTNews — RTTNews positive
- NEWS ALMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus — GuruFocus neutral
- NEWS Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript - AOL.com — AOL.com neutral
- NEWS Alamar Biosciences Shares (ALMR) Surge 31% as Consumables Drive Gross Margin Up - TechStock² — TechStock² positive
Generated 2026-11-02T11:43:19Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $30.60, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8). Chart setup: No clear chart pattern; technical signals are mixed. Downgraded from BUY WAIT — price $30.60 has reached target $30.80. No upside to wait for. Analyst target $30.80 (+0.6%), stop $22.29 (−37.3%), A.R:R 0.0:1. Score 5.8/10, moderate confidence.
Analyst target: $30.80 (+0.6% upside). Analyst target $30.80 (+0.6%), stop $22.29 (−37.3%), A.R:R 0.0:1. Stop-loss: $22.29.
Analyst target reached - limited upside remaining; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8); Expensive valuation.
Alamar Biosciences, Inc. trades at a P/E of N/A (forward -67.7). TrendMatrix value score: 3.0/10. Verdict: Hold.
11 analysts cover ALMR with a consensus score of 4.2/5. Average price target: $35.
What does Alamar Biosciences, Inc. do?Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments,...
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.